Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPN | P05981 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17715427 | 0.86 | MAOA (0.55) | PNMTPDCD1CD274POLBHTR2B | |
| SCHEMBL7189694 | 0.86 | DRD3 (0.51) | DRD2DRD4DRD3PNMTPOLB | |
| SCHEMBL2313142 | 0.85 | DRD2 (0.46) | DRD2DRD4DRD3PNMTPDCD1 | |
| SCHEMBL7184376 | 0.84 | DRD2 (0.50) | DRD2DRD4DRD3PNMTPOLB | |
| SCHEMBL5540652 | 0.81 | DRD3 (0.48) | DRD2DRD4DRD3PNMTPOLB | |
| SCHEMBL21694426 | 0.81 | DRD2 (0.48) | DRD2DRD4DRD3PNMTPOLB | |
| SCHEMBL16792809 | 0.81 | PNMT (0.62) | DRD2DRD4DRD3PNMTPOLB | |
| SCHEMBL28747863 | 0.81 | DRD3 (0.48) | DRD2DRD4DRD3PNMTPOLB | |
| SCHEMBL9762612 | 0.81 | DRD2 (0.48) | DRD2DRD4DRD3PNMTPOLB | |
| SCHEMBL9940488 | 0.79 | AKR1B1 (0.47) | DRD2DRD4DRD3PNMTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5210352-A | Fluorene compounds | PHILLIPS PETROLEUM COMPANY (US) | 1993-05-11 | — | — | US | claimed |
| US-20240360319-A1 | SUBSTITUTED POLYFLUORENE COMPOUNDS | BioLegend, Inc. | 2024-10-31 | — | — | US | disclosed |
| US-12091554-B2 | Substituted polyfluorene compounds | BioLegend, Inc. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20220002552-A1 | SUBSTITUTED POLYFLUORENE COMPOUNDS | BioLegend, Inc. (US) | 2022-01-06 | — | — | US | disclosed |
| US-11155714-B2 | Substituted polyfluorene compounds | BioLegend, Inc. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20190203052-A1 | SUBSTITUTED POLYFLUORENE COMPOUNDS | BIOLEGEND (US) | 2019-07-04 | — | — | US | disclosed |
| WO-2018009861-A1 | SUBSTITUTED POLYFLUORENE COMPOUNDS | BIOLEGEND (US) | 2018-01-11 | — | — | WO | disclosed |
| CN-107501316-A | LUMEFANTRINE isomers and preparation method thereof | 安徽贝克联合制药有限公司 | 2017-12-22 | — | — | CN | disclosed |
| CN-107095871-A | Quisinostat, a novel highly effective antimalarial drug | 中国科学院上海巴斯德研究所 | 2017-08-29 | — | — | CN | disclosed |
| CN-1964965-B | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE | 2012-07-04 | — | — | CN | disclosed |
| US-5436305-A | Preparing polymer catalysts by reaction of alkali metal alkyl and fluorenyl in solvent | PHILLIPS PETROLEUM COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| US-5406013-A | Cyclopentadiene type compounds and method for making | PHILLIPS PETROLEUM COMPANY (US) | 1995-04-11 | — | — | US | disclosed |
| US-5393911-A | Cyclopentadiene type compounds and method for making | PHILLIPS PETROLEUM COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0577581-A2 | Method for controlling the melting points and molecular weights of syndiotactic polyolefins using metallocene catalyst systems | FINA TECHNOLOGY, INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| US-5210352-A | Fluorene compounds | PHILLIPS PETROLEUM COMPANY (US) | 1993-05-11 | — | — | US | disclosed |
| US-5191132-A | CYCLOPENTADIENE TYPE COMPOUNDS AND METHOD FOR MAKING | PHILLIPS PETROLEUM COMPANY (US) | 1993-03-02 | — | — | US | disclosed |
| CN-1068829-A | Organometallic fluorenyl compounds and preparation thereof and application | PHILLIPS PETROLEUM CO (US) | 1993-02-10 | — | — | CN | disclosed |
| EP-0524624-A2 | Organometallic fluorenyl compounds, preparation, and use | PHILLIPS PETROLEUM COMPANY (US) | 1993-01-27 | — | — | EP | disclosed |
| CN-1066440-A | Cyclopeutadiene type compounds and preparation method thereof | PHILLIPS PETROLEUM CO (US) | 1992-11-25 | — | — | CN | disclosed |
| EP-0512554-A2 | Cyclopetadiene type compounds and method for making | PHILLIPS PETROLEUM COMPANY (US) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155714-B2 | Substituted polyfluorene compounds | PARG, PFAS, PARN | DRD2 4387/4885DRD4 3731/4885DRD3 3965/4885 |
| US-20240360319-A1 | SUBSTITUTED POLYFLUORENE COMPOUNDS | PARG, PFAS, PARN | DRD2 4387/4885DRD4 3731/4885DRD3 3965/4885 |
| US-20220002552-A1 | SUBSTITUTED POLYFLUORENE COMPOUNDS | PARG, PFAS, PARN | DRD2 4387/4885DRD4 3731/4885DRD3 3965/4885 |
| US-12091554-B2 | Substituted polyfluorene compounds | PARG, PFAS, PARN | DRD2 4387/4885DRD4 3731/4885DRD3 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.